Onychomycosis News and Research

RSS

Onychomycosis (also known as "Dermatophytic onychomycosis," "Ringworm of the nail," It is the most common disease of the nails and constitutes about a half of all nail abnormalities.

NexMed provides update on Vitaros NDS with Health Canada

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today provided an update on the status of its New Drug Submission ("NDS") with Health Canada for Vitaros®, the Company's topical treatment for erectile dysfunction.

11 Jun 2010

Celtic Pharma commences enrolment in Phase III trial of TDT 067 for onychomycosis

Celtic Pharmaceutical Holdings L.P., the global private equity firm focused on the biotechnology and pharmaceutical industries, announced today the enrolment of the first patient into its Phase III trial of TDT 067, terbinafine in Transfersomes®, for the topical treatment of onychomycosis (also known as a fungal nail infection).

30 Apr 2010

NovaBay Pharmaceuticals reports net income of $2.7M for 2009 against year-ago loss

NovaBay Pharmaceuticals, Inc., a clinical stage specialty pharmaceutical company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, today reported full-year and fourth quarter financial results for 2009. The company also highlighted recent progress of its proprietary and partnered development programs.

30 Mar 2010

BeaconEquity.com announces investment report featuring NexMed

BeaconEquity.com announces an investment report featuring NexMed Inc. (Nasdaq:NEXM). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

12 Mar 2010

Merck returns worldwide development and commercialization rights for AN2690 to Anacor Pharmaceuticals

Anacor Pharmaceuticals announced today that Merck has returned full worldwide development and commercialization rights for AN2690 to Anacor. AN2690 is a topical anti-fungal therapy being developed for onychomycosis, a fungal infection of the nail and nail bed. It is estimated that onychomycosis affects approximately 35 million people in the United States.

12 Feb 2010

TOPICA's IND for onychomycosis antifungal agent accepted by FDA

TOPICA Pharmaceuticals, a privately-held biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug (IND) application for the use of luliconazole, its lead product candidate, in patients with onychomycosis (nail and nail bed fungal infections).

1 Feb 2010

Galderma S.A. offers $3.75 million to NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a new class of anti-infectives for treating multi-drug resistant pathogens, announced today that it has received $3.75 million in milestone payments from partner Galderma S.A.

11 Jan 2010

NexMed updates corporate activities

NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today provided an update on ongoing corporate activities and the status of the Company’s NASDAQ listing.

9 Jan 2010

Pilot clinical study results of laser treatment for toenail fungus presented

PinPointe USA, Inc., a privately held emerging medical technology company which introduced the breakthrough PinPointe FootLaser treatment for toenail fungus in Europe, today announced that Dr. Brian McDowell presented the results of his pilot clinical study “Laser Treatment for Toenail Fungus” (Harris, McDowell and Strisower, Proc. SPIE 7161A, 2009) at the Society of Chiropodists and Podiatrists Annual Conference 2009 at Harrogate International Centre on November 19.

25 Nov 2009

NovaBay Pharmaceuticals' Aganocide compounds demonstrate potent antifungal activity against onychomycosis

NovaBay Pharmaceuticals, Inc. today announced that its Aganocide® compounds demonstrate potent antifungal activity in an established pre-clinical infected nail model of onychomycosis. The study data will be presented tomorrow at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia.

31 Oct 2009

Genetic mutations may put individuals at increased risk for fungal infections

New research has identified two genetic mutations that may put individuals at increased risk for fungal infections. The research focused on patients with severe fungal infections (primarily of the genus Candida), but the findings may also have implications for patients who have more common mild infections.

29 Oct 2009

Keraderm raises $2.5 million from institutional investor

Keraderm Corp. announced the closing today of a $2.5 million dollar Series A investment by NewVa Capital Partners, LP. Currently starting clinical trials, the company's platform harnesses phototherapy technology to treat nail and skin infections. NewVa Capital Partners is a private equity and venture capital fund managed by Third Security, LLC and provides early stage investments in companies located or considering location in the NewVa region of southwest Virginia. This is Keraderm's first institutional investment round.

24 Oct 2009

NexMed completes its post hoc analysis of NM100060

NexMed, Inc., a developer of products based on the NexACT® technology, today announced that it has completed its post hoc analysis of NM100060, the Company’s topically-applied treatment for onychomycosis, commonly known as nail fungus. Based on this analysis, NexMed seeks to pursue signing a partner for further development of the product.

15 Oct 2009

Phase 2 clinical study results of TOPICA's luliconazole for athlete's foot announced

TOPICA Pharmaceuticals, a privately-held biotechnology company, today announced positive results from its Phase 2 clinical study evaluating luliconazole, one of the most potent and broad spectrum topical antifungal agents, in patients with tinea pedis (athlete's foot). The study was designed to assess the effectiveness of 1% luliconazole cream applied once daily for 14 days compared with once daily for 28 days.

6 Oct 2009

Nomir publishes efficacy of the Noveondual-wavelength device against infectious disease pathogens

Nomir Medical Technologies, a leader in the development of optical energy technologies for medical applications, announced today the publication of a scientific paper in the journal Photochemistry and Photobiology that details in vitro and human data demonstrating the unique and patented mechanism-of-action for its Noveon® dual-wavelength device, as well as positive efficacy and safety data.

16 Sep 2009

NanoBio demonstrates new topical approach to treating nail fungus that circumvents problems with current therapy

A novel topical therapy for nail fungus, NB-002, has demonstrated a new topical approach to healing nail fungus by penetrating skin pores and diffusing through the skin that surrounds the entire nail plate, according to a study conducted by NanoBio Corporation.

27 Oct 2008

MacroChem acquires Virium Pharmaceuticals

MacroChem Corporation announced today that on April 18, 2008 it acquired Virium Pharmaceuticals Inc., a non-public, development stage company developing and commercializing novel therapeutics, with a portfolio of clinical stage product candidates focused in oncology, including its next generation nucleoside analogue licensed from the Southern Research Institute.

23 Apr 2008

NanoBio completes interim analysis of phase 2 clinical trial in onychomycosis

NanoBio Corporation has announced that it has seen promising results from an interim analysis of its phase 2 study of NB-002, a topical lotion for onychomycosis (nail fungus). Although the details remain confidential, the results clearly justify completing the study, according to NanoBio scientists

24 Mar 2008

Nasal vaccine for smallpox protects animals against 77 times the potentially lethal dose of smallpox

Scientists at NanoBio Corporation and the University of Michigan have demonstrated their nasally delivered vaccinia vaccine can protect animals against 77 times the potentially lethal dose of smallpox, and without the safety risks of current vaccines for smallpox.

27 Feb 2008

NanoBio expands drug development team

NanoBio Corporation has announced the addition of four new scientists to its drug development team.

26 Sep 2007